Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Study finds mRNA-based COVID-19 vaccines are effective in cancer patients

The mRNA-based COVID-19 vaccines are effective at preventing infection in most cancer patients, according to a nationwide study of veterans diagnosed with cancer in the past decade.

6 Dec 2021

Study shows COVID booster shots work

A new study investigates uses seven different COVID-19 vaccines as the third dose to boost immunity in vulnerable patients.

6 Dec 2021

Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination

A new study supports the hypothesis that heterologous vaccination can provide an increased immune response against virus infection, supporting several other studies that have indicated similar events.

5 Dec 2021

A case of post-vaccination MIS in an adult without prior SARS-CoV-2 infection

A new case study on the report of multisystem inflammatory syndrome (MISC) in a 22-year-old woman in South Korea after vaccination.

5 Dec 2021

Plant-derived virus-like particle vaccines against SARS-CoV-2

In a review published in Biotechnology Letters, the authors discuss plant-derived VLP-based vaccines.

1 Dec 2021

Custom Biofluid & Tissue Procurement Service

Global provider of human and animal biospecimens - AMSBIO offers a custom procurement service enabling researchers to source specific biofluid and tissue samples which are not already available in their extensive biorepository.

From AMS Biotechnology 1 Dec 2021

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

29 Nov 2021

Do we need COVID-19 vaccine boosters?

An article published recently in the Journal of Virology explored the science behind COVID-19 vaccine boosters.

29 Nov 2021

COVID vaccines effectively reduce outbreaks of SARS-CoV-2 alpha and delta viruses in households

A team of UK-based scientists has recently evaluated the effectiveness of coronavirus disease 2019 (COVID-19) vaccines in preventing household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in England.

28 Nov 2021

SARS-CoV-2 Delta variant mutation sites

A new review article dissected the sites of mutation in the RBD of the Delta variant and other variants of concern and variants of alert and interest.

25 Nov 2021

Breakthrough infections from SARS-CoV-2 Delta variant among vaccinated healthcare workers

A new study published on the medRxiv* preprint server employed in-silico techniques, combining genomic and epidemiological data, to determine possible Delta-variant transmission events between vaccinated healthcare workers (HCWs) in Indian hospitals.

25 Nov 2021

Scientists discover several factors influencing waning immunity with the Pfizer COVID Vaccine

New research from Japan found several risk factors associated with greater waning immunity after vaccination. Old age and smoking were amongst those with some of the lowest antibody titers. Women more than men were also more likely to experience a rapid decline in antibody levels 3 to 6 months after receiving their second Pfizer-BioNTech dose.

21 Nov 2021

Unprecedented manufacturing strategy provides a template for equitable supply of vaccines

Today, as AstraZeneca reports 2 billion doses of the COVID-19 vaccine released for supply University of Oxford scientists explain how it has been possible to produce so much of the vaccine in less than a year, and the unprecedented strategy used to improve international equity of access.

16 Nov 2021

SARS-CoV-2 self-amplifying mRNA vaccine demonstrates cellular and humoral immune responses

Researchers from the US recently reported the preclinical development of a self-amplifying mRNA (SAM) vaccine that encodes a prefusion-stabilized SARS-CoV-2 spike glycoprotein.

12 Nov 2021

University of Oxford begins Phase I trial to test Ebola vaccine

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers - with the first vaccinations taking place today (Thursday, 11 November).

11 Nov 2021

Immunity following COVID-19 vaccination and natural infection in India

The researchers evaluated immune response markers in a cross-section of people from the Indian state of West Bengal, including those vaccinated with either Covishield or Covaxin, the unvaccinated cohort, and the naturally infected.

11 Nov 2021

Finnish study highlights the need for mRNA COVID vaccine booster shots

A register-based cohort study of the effectiveness of COVID-19 vaccines was performed to help decision-making on providing booster doses to social and healthcare workers (HCWs) like nurses, physicians, dentists, and other professionals in Finland. In addition, it estimated the vaccine effectiveness after the second dose. This study is published on the medRxiv* preprint server.

9 Nov 2021

A measles-vectored COVID-19 vaccine induces strong immunity in animal model

A new study explores the potential of MV-based vaccines targeting the S protein of SARS-CoV-2.

9 Nov 2021

Ad26.COV2.S vaccine effectiveness for preventing COVID-19

A group of multi-national researchers has expanded on previous research to conduct a preliminary evaluation of the effectiveness of the Ad26.COV2.S vaccine via HER data.

8 Nov 2021

Rapid antibody response induced by mRNA COVID vaccines in mice

A new study posted in the bioRxiv* preprint server used mouse models to investigate how mRNA vaccines elicit a rapid antibody response. Their findings show two different mRNA vaccines successfully boost antibody levels — IL-5, IL-6, and MCP-1 —5 days after administration.

7 Nov 2021